The patients included in this retrospective study met the following inclusion criteria: 1) a diagnosis of HCC or ICC confirmed by radiological or pathological findings according to the AASLD practice guidelines (Heimbach et al., 2018); 2) received at least one dose of ICIs, including PD-1 inhibitors (sintilimab, camrelizumab, pembrolizumab, tislelizumab, toripalimab, and nivolumab) or PD-L1 inhibitors (atezolizumab). This evidence concerns the gene CD274 and hepatocellular carcinoma.